^
    1d
    Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=258, Not yet recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P3 trial
    3d
    Interventional: MHB018A Treatment in Patients With Chronic Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, Minghui Pharmaceutical (Hangzhou) Ltd
    New P3 trial
    10d
    A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) (clinicaltrials.gov)
    P3, N=284, Active, not recruiting, Viridian Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    10d
    Unveiling disulfidptosis-linked lncRNA signatures: insights into the immune microenvironment and drug responsiveness in oral squamous cell carcinoma. (PubMed, Front Genet)
    12 drugs were identified for OSCC treatment, such as BMS-754807_2171 and Foretinib_2040. Our study identified 9 DE-DRLs correlated with OSCC, which will be a personalized prediction tool for prognosis and immune responses in OSCC patients.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CD4 (CD4 Molecule)
    |
    TMB-H
    |
    BMS-754807 • foretinib (GSK1363089)
    11d
    Chryseobacterium indologenes mediates resistance to osimertinib by activating the IGF1R pathway in EGFR-mutant lung adenocarcinoma. (PubMed, bioRxiv)
    PCM did not enhance cell viability when IGF1R was silenced or inhibited with linsitinib, demonstrating the pathway's essential role. Finally, PCM also conferred resistance to osimertinib in patient-derived EGFR-mutant lung adenocarcinoma cell lines. Our study demonstrates that the intra-tumoral bacteria C. indologenes may significantly influence sensitivity to osimertinib or impart resistance in EGFR-mutant lung adenocarcinoma by activating the IGF1R signaling pathway.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • linsitinib (ASP7487)
    15d
    MHB018A Treatment in Patients With Active Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=108, Recruiting, Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=111, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    18d
    Construction and validation of a disulfidptosis-related risk assessment model for prediction of prognosis, immune microenvironment, drug therapy and microbiota in patients with low grade glioma. (PubMed, Int J Surg)
    Through drug sensitivity analysis, several drugs exhibited significant correlation with risk score, and molecular docking illustrated that both dactolisib and linsitinib were capable of binding tightly with most signature genes, making them potential candidates for targeted therapeutic approaches of LGG. Thus, this model can stratify LGG patients with distinct gene expression features, immune landscape, genomic instability and microbiota features. By stratifying patients with risk score, this risk model may improve the accuracy of prognostic prediction for LGG patients, which might provide new insights into the molecular targeted therapy for individual treatment in a risk score-specific manner.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    dactolisib (RTB101) • linsitinib (ASP7487)
    28d
    A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease (clinicaltrials.gov)
    P1/2, N=88, Recruiting, Amgen | Phase classification: P1 --> P1/2
    Phase classification
    1m
    Effectiveness and Safety of Teprotumumab in patients with thyroid eye disease (ChiCTR2500108068)
    P=N/A, N=42, Not yet recruiting, Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital
    New trial
    |
    Tepezza (teprotumumab-trbw)
    1m
    A Phase 1 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1, N=253, Active, not recruiting, Fusion Pharmaceuticals Inc. | Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | Trial completion date: Jun 2026 --> Dec 2025 | Trial primary completion date: Apr 2026 --> Dec 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1)
    |
    HER-2 negative
    |
    FPI-1434
    2ms
    A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease (clinicaltrials.gov)
    P3, N=99, Not yet recruiting, Zai Lab (Shanghai) Co., Ltd.
    New P3 trial